ZA200901425B - Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists - Google Patents

Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Info

Publication number
ZA200901425B
ZA200901425B ZA200901425A ZA200901425A ZA200901425B ZA 200901425 B ZA200901425 B ZA 200901425B ZA 200901425 A ZA200901425 A ZA 200901425A ZA 200901425 A ZA200901425 A ZA 200901425A ZA 200901425 B ZA200901425 B ZA 200901425B
Authority
ZA
South Africa
Prior art keywords
sensitization
administration
tumor cells
radiation therapy
endothelin agonists
Prior art date
Application number
ZA200901425A
Other languages
English (en)
Inventor
Anil Gulati
Guru Reddy
Luigi Lenaz
Original Assignee
Spectrum Pharmaceuticals Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc, Univ Illinois filed Critical Spectrum Pharmaceuticals Inc
Publication of ZA200901425B publication Critical patent/ZA200901425B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
ZA200901425A 2006-08-31 2009-02-27 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists ZA200901425B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82419706P 2006-08-31 2006-08-31

Publications (1)

Publication Number Publication Date
ZA200901425B true ZA200901425B (en) 2010-04-28

Family

ID=38920900

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901425A ZA200901425B (en) 2006-08-31 2009-02-27 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Country Status (15)

Country Link
US (2) US8394757B2 (no)
EP (1) EP2059254B1 (no)
JP (1) JP5306208B2 (no)
KR (1) KR101547361B1 (no)
CN (1) CN101534852B (no)
BR (1) BRPI0722292A2 (no)
CA (1) CA2661833C (no)
DK (1) DK2059254T3 (no)
ES (1) ES2541657T3 (no)
IL (1) IL197335A (no)
MX (1) MX2009002308A (no)
NO (1) NO20091203L (no)
RU (1) RU2009111605A (no)
WO (1) WO2008027839A1 (no)
ZA (1) ZA200901425B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
CN101534852B (zh) 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
KR20100057060A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
WO2017051923A1 (ja) 2015-09-25 2017-03-30 日本化薬株式会社 アゾ化合物、インク組成物、インクジェット記録方法及び着色体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU686018B2 (en) 1994-09-20 1998-01-29 Amcor Packaging (New Zealand) Limited A container
EP1609477B1 (en) 1994-12-12 2011-11-09 Omeros Corporation Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
GB9910155D0 (en) 1999-04-30 1999-06-30 Microbiological Research Agenc Augmented agglutination assay
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
JP2003535061A (ja) 2000-05-31 2003-11-25 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー エンドセリン受容体拮抗剤および疼痛軽減特性を有する抗癲癇化合物または鎮痛剤の複合物
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
WO2006057988A2 (en) * 2004-11-22 2006-06-01 The Board Of Trustees Of The University Of Illinois Use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging
JP2008531589A (ja) 2005-02-22 2008-08-14 スペクトラム・ファーマシューティカルス・インコーポレーテッド 固形腫瘍の治療に貢献するための方法、組成物及び製品
CN101534852B (zh) 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化

Also Published As

Publication number Publication date
DK2059254T3 (en) 2015-07-13
US8394757B2 (en) 2013-03-12
CA2661833A1 (en) 2008-03-06
BRPI0722292A2 (pt) 2014-04-15
JP2010502638A (ja) 2010-01-28
US20130150649A1 (en) 2013-06-13
MX2009002308A (es) 2009-09-07
CN101534852B (zh) 2013-02-13
CA2661833C (en) 2016-01-26
IL197335A (en) 2013-07-31
US20080318846A1 (en) 2008-12-25
JP5306208B2 (ja) 2013-10-02
KR20090069279A (ko) 2009-06-30
ES2541657T3 (es) 2015-07-23
EP2059254B1 (en) 2015-04-08
NO20091203L (no) 2009-03-23
CN101534852A (zh) 2009-09-16
KR101547361B1 (ko) 2015-08-25
IL197335A0 (en) 2011-08-01
WO2008027839A1 (en) 2008-03-06
US8957014B2 (en) 2015-02-17
EP2059254A1 (en) 2009-05-20
RU2009111605A (ru) 2010-10-10

Similar Documents

Publication Publication Date Title
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
IL216283A0 (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
EP2231165A4 (en) METHOD FOR DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE TO CANCER CHEMOTHERAPY WITH HERZGLYCOSIDE
IL197335A0 (en) Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
HK1224200A1 (zh) 用於治療胰腺癌的藥物
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
IL243741A0 (en) Anti-angiogenic therapy for the treatment of breast cancer
ZA201004403B (en) Therapeutic cancer treatments
IL195371A0 (en) Mobile radiation therapy
EP2356446A4 (en) DIAGNOSTIC AND THERAPEUTIC METHODS RELATING TO CANCER STEM CELLS
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
DE602007000788D1 (de) Vielblattkollimator und Strahlentherapieanlage
GB0921596D0 (en) Particles for the treatment of cancer in combination with radiotherapy
IL201460A0 (en) Phthalazinone derivatives and their use as medicament to treat cancer
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
EP2432539A4 (en) HYPERTHERMIA ASSISTED RADIOTHERAPY
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
EP2195425A4 (en) PKIB AND NAALADL2 FOR TARGET GENES OF THERAPY AND DIAGNOSIS OF PROSTATE CANCER
PL399129A1 (pl) Fulvestrant w dawce 500 mg do leczenia zaawansowanego nowotworu piersi
IL206189A0 (en) Compound for use in the treatment of cancer
WO2011056566A3 (en) Compounds and methods for treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP2419111A4 (en) CANCER THERAPY SENSITIZING AGENTS, METHODS OF USE, AND METHODS OF IDENTIFYING THESE AGENTS
EP2336108A4 (en) TRIPYRROL-OCTAARGININE HYBRID COMPOUNDS AND USE THEREOF AS A MEDICAMENT FOR TREATING CANCER AND MICROBIAL DISEASES